Study guide

6.1 Antidiabetic Agents, Metformin Lactic Acidosis, and Thyroid Hormone

Certified Specialist in Poison Information CSPI

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Pharmacology & Toxicology Principles

1.1 Toxicokinetics: Absorption, Distribution, Metabolism, and Elimination Alterations in Overdose 1.2 Toxicodynamics, Receptor Pharmacology, and Dose-Response Relationships 1.3 Cellular and Biochemical Mechanisms of Toxicity 1.4 Hepatic Biotransformation, Phase I/II Reactions, and CYP450 Interactions

2 Chapter 2: Poison Center Case Assessment Fundamentals

2.1 Exposure History: The Questions That Change Management 2.2 Toxicologic Calculations: Doses, Concentrations, and Conversions

3 Chapter 3: Analgesics, Opioids & Over-the-Counter Medications

3.1 Acetaminophen Overdose: Pathophysiology, Rumack-Matthew Nomogram, and NAC Protocols 3.2 Salicylates: Pathophysiology, Acid-Base Derangements, and Urinary Alkalinization 3.3 Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and Miscellaneous OTC Analgesics 3.4 Opioids, Opioid Toxidrome, and Naloxone Titration 3.5 Cough and Cold Products, Antihistamines, Muscle Relaxants, and Local Anesthetics

4 Chapter 4: Psychotropic & Neurologic Medications

4.1 Tricyclic and Cyclic Antidepressants: Cardiotoxicity, ECG Findings, and Bicarbonate Therapy 4.2 SSRIs, SNRIs, Novel Antidepressants, and Serotonin Syndrome 4.3 Antipsychotics, Neuroleptic Malignant Syndrome, and Lithium Neurotoxicity 4.4 Benzodiazepines, Z-drugs, Barbiturates, and Major Anticonvulsants

5 Chapter 5: Cardiovascular Drugs & Substances of Abuse

5.1 Beta-Blockers, Calcium Channel Blockers, and High-Dose Insulin Euglycemia Therapy 5.2 Digoxin and Cardiac Glycosides: Mechanism, Arrhythmias, and Digoxin Immune Fab 5.3 Sympathomimetics, Cocaine, Amphetamines, Synthetic Cannabinoids, and Hallucinogens 5.4 Caffeine, Theophylline, and Over-the-Counter Stimulants 5.5 Cannabis, GHB, Nitrites, and Nicotine Products

6 Chapter 6: Endocrine, Antimicrobial & Miscellaneous Medications

6.1 Antidiabetic Agents, Metformin Lactic Acidosis, and Thyroid Hormone 6.2 Antimicrobials, Vitamins and Minerals, and Veterinary Products

7 Chapter 7: Household, Chemical & Inhalational Toxins

7.1 Caustic and Corrosive Ingestions: Acids vs. Alkalis, Tissue Necrosis, and Endoscopic Grading 7.2 Cleaning Products, Personal Care Products, and Household Chemicals 7.3 Hydrocarbons and Halogenated Solvents: Aspiration Risks and Myocardial Sensitization 7.4 Carbon Monoxide, Cyanide, Hydrogen Sulfide, and Inhalational Irritants

8 Chapter 8: Pesticides, Heavy Metals & Toxic Alcohols

8.1 Organophosphates, Carbamates, Pyrethroids, and Cholinesterase Antidotes 8.2 Rodenticides, Herbicides, Repellents, and Other Pesticides 8.3 Ethylene Glycol, Methanol, and Isopropanol: Metabolism, Osmolal Gaps, and Fomepizole 8.4 Lead, Mercury, Arsenic, Iron Toxicity, and Chelation Protocols

9 Chapter 9: Toxic Plants, Mushrooms & Foodborne Toxins

9.1 Toxic Plants: Cardiac Glycosides, Anticholinergics, Nicotinics, and Sodium Channel Activators 9.2 Oxalate, Irritant, Hallucinogenic, and Stimulant Plants 9.3 Mushroom Poisoning: Amatoxins, Monomethylhydrazine, Muscarine, and Coprine 9.4 Scombroid, Ciguatera, Tetrodotoxin, Paralytic Shellfish, and Botulism 9.5 Bacterial Foodborne Illness and Food Poisoning Triage

10 Chapter 10: Envenomations & Bites

10.1 North American Pit Vipers (Crotalinae): Envenomation Assessment and Antivenom Management 10.2 Elapid Snakebites (Coral Snakes): Neurotoxicity, Clinical Course, and Antivenin 10.3 Black Widow, Brown Recluse Spiders, and Bark Scorpion Stings 10.4 Hymenoptera Stings, Ticks, and Other Arthropods 10.5 Marine Envenomations: Jellyfish, Stingrays, Catfish, and Lionfish

11 Chapter 11: Clinical Assessment, Toxidromes & Triage

11.1 Recognition of Classic Toxidromes and Vital Sign Pattern Analysis 11.2 Severity Assessment, Exposure Urgency, and Poison Center Telephone Triage Flow 11.3 Home Observation vs. Emergency Department Referral Decision-Making 11.4 Diagnostic Toxicology: Acid-Base Analysis, Gaps, ECG Intervals, and Drug Testing

12 Chapter 12: Decontamination, Antidotes & Elimination

12.1 Gastrointestinal Decontamination: Activated Charcoal, Whole Bowel Irrigation, and Contraindications 12.2 Essential Poison Center Antidotes: Indications, Mechanisms, and Titration Pearls 12.3 Enhanced Elimination: Urinary Alkalinization, MDAC, Hemodialysis, and Hemoperfusion 12.4 Resuscitation and Supportive Care: Seizures, Hyperthermia, and Hemodynamic Shock

13 Chapter 13: Pediatric Poisoning & High-Risk Hazards

13.1 Pediatric "One-Pill-Can-Kill" Agents and Pediatric Toxic Dose Thresholds 13.2 Button Batteries, Rare-Earth Magnets, and Expandable Foreign Bodies 13.3 Developmental Ingestion Patterns, Liquid Detergent Pods, and Essential Oils

14 Chapter 14: Communication, NPDS Documentation & Prevention

14.1 Emergency Call Communication, Panicked Callers, and Healthcare Provider Consultations 14.2 National Poison Data System (NPDS) Coding Standards and Medical Outcome Categorization 14.3 Scheduled Follow-up Protocols, Medical Toxicologist Consultation Triggers, and Public Health Surveillance 14.4 Evidence-Based Poison Prevention, PPPA Regulations, and Community Outreach

6.1 Antidiabetic Agents, Metformin Lactic Acidosis, and Thyroid Hormone

Key Takeaways Explain This Topic AI

Sulfonylureas and meglitinides cause insulin secretion independent of glucose, so hypoglycemia is delayed, prolonged, and recurs after dextrose boluses; octreotide suppresses the insulin release and is the targeted therapy.

Metformin does not cause hypoglycemia by itself; its lethal manifestation is metformin-associated lactic acidosis, and EXTRIP recommends extracorporeal treatment for lactate above 20 mmol/L, pH of 7.0 or less, or failure of standard care, with shock or kidney impairment lowering the threshold.

Insulin overdose produces prolonged hypoglycemia with hypokalemia and requires continuous concentrated dextrose infusions guided by frequent glucose checks; octreotide does not help because the insulin is exogenous.

Glucagon-like peptide-1 agonists rarely cause hypoglycemia alone but produce marked vomiting and delayed gastric emptying, which matters for both aspiration risk and absorption of co-ingested drugs.

Acute levothyroxine ingestion, even of large amounts in children, usually causes only mild delayed adrenergic symptoms appearing over 2 to 7 days, and treatment is a beta-blocker for symptoms rather than aggressive intervention.

Last updated: September 2026

Insulin Secretagogues: Sulfonylureas and Meglitinides

Sulfonylureas (glipizide, glyburide, glimepiride, chlorpropamide) bind the SUR1 subunit of the pancreatic beta cell ATP-sensitive potassium channel, closing it. The membrane depolarizes, voltage-gated calcium channels open, and insulin is released regardless of the blood glucose . Meglitinides (repaglinide, nateglinide) act at the same channel with a shorter duration.

Why the Hypoglycemia Is Dangerous

Delayed onset. Hypoglycemia commonly appears 8 to 18 hours after ingestion, and later with extended-release products or in kidney impairment.

Recurrence after dextrose. A dextrose bolus raises glucose, which then stimulates further insulin release from drug-primed beta cells, so the patient crashes again.

Duration. Effects last 24 hours or more, especially with glyburide and chlorpropamide.

One tablet can harm a toddler , which is why any credible pediatric exposure is referred and observed for at least 24 hours with serial glucose measurement.

Management

Step Detail

Do not give prophylactic dextrose Feeding a normoglycemic patient dextrose provokes more insulin release; treat documented hypoglycemia

Treat hypoglycemia Dextrose 0.5 to 1 g/kg intravenously (D10 or D25 in children, D50 in adults), then a maintenance dextrose-containing infusion and food if the patient can eat

Octreotide 1 to 1.25 mcg/kg (commonly 50 mcg in adults) subcutaneously or intravenously every 6 to 12 hours; suppresses insulin secretion and reduces the number of recurrent hypoglycemic episodes

Monitoring Hourly bedside glucose initially, then at least every 2 hours; observe at least 24 hours after the last hypoglycemic episode and after the last octreotide dose

  • Glucagon Only a temporizing measure when no access exists; requires hepatic glycogen and provokes vomiting
  • Metformin

Metformin is a biguanide that reduces hepatic gluconeogenesis and increases peripheral glucose uptake. It does not stimulate insulin release, so hypoglycemia is uncommon unless the patient is fasting, has liver disease, or took another agent.

Metformin-Associated Lactic Acidosis

By inhibiting mitochondrial complex I and hepatic pyruvate carboxylase, metformin blocks the conversion of lactate to glucose and shifts metabolism toward anaerobic glycolysis. The result is a severe anion gap lactic acidosis.

Risk factors: kidney impairment (the drug is renally cleared), acute illness, dehydration, sepsis, heart failure, alcohol use, and massive intentional overdose.

Presentation: vomiting, abdominal pain, hyperventilation, hypotension, hypothermia, and altered mental status with lactate that can exceed 15 to 25 mmol/L. Mortality rises steeply with pH below 7.1.

Management: volume resuscitation, treatment of the precipitating illness, and early extracorporeal treatment . EXTRIP recommends ECTR when lactate exceeds 20 mmol/L , when pH is 7.0 or less , or when standard supportive measures fail, and suggests it for lactate of 15 to 20 mmol/L or pH of 7.0 to 7.1. Shock, impaired kidney function, liver failure, or decreased consciousness lower the threshold for starting it. Bicarbonate-buffered intermittent hemodialysis is preferred, and treatment continues until lactate is below 3 mmol/L and pH is above 7.35.

Exogenous Insulin

Deliberate or accidental insulin overdose, including injection of long-acting analogues, produces hypoglycemia lasting far beyond the usual therapeutic duration because a subcutaneous depot continues to absorb.

Management: continuous concentrated dextrose infusion (D10 peripherally, D20 or higher centrally) titrated to glucose of about 100 to 150 mg/dL, frequent bedside checks, oral intake when safe, and repletion of potassium, magnesium, and phosphate , which shift intracellularly.

Octreotide does not work , because the problem is injected insulin rather than pancreatic secretion.

Observation is prolonged: 24 hours or more for long-acting analogues, and local excision of an injection site is a historical measure that is rarely used.

Other Diabetes Medications

Class Overdose Behavior

Glucagon-like peptide-1 receptor agonists (semaglutide, liraglutide, tirzepatide) Profound nausea, vomiting, and delayed gastric emptying; hypoglycemia uncommon alone but likely if combined with insulin or a secretagogue. Delayed gastric emptying can prolong absorption of co-ingested drugs

Dipeptidyl peptidase-4 inhibitors (sitagliptin) Generally mild; hypoglycemia mainly with a secretagogue

Sodium-glucose cotransporter-2 inhibitors (empagliflozin) Osmotic diuresis and volume depletion; euglycemic ketoacidosis is the characteristic hazard

Thiazolidinediones (pioglitazone) Low acute toxicity; fluid retention

Alpha-glucosidase inhibitors (acarbose, miglitol) Flatulence and diarrhea; if hypoglycemia occurs with a co-ingestant, oral sucrose will not work because its breakdown is blocked, so glucose (dextrose) must be used

Thyroid Hormone

Levothyroxine (T4) and liothyronine (T3) increase the transcription of genes governing metabolic rate, and they up-regulate beta-adrenergic responsiveness. Two pharmacologic facts explain the clinical course.

Conversion and distribution take time. T4 must be deiodinated to T3, and the half-life of T4 is about 7 days, so effects appear over days rather than hours.

Acute single ingestions are usually benign. Children who swallow even large numbers of levothyroxine tablets most often remain asymptomatic. When symptoms occur they appear 2 to 7 days later and are mild: tachycardia, irritability, tremor, diarrhea, sweating, and insomnia.

Practical Approach

Scenario Action

Asymptomatic child, acute levothyroxine ingestion Most centers observe at home with follow-up calls over the next several days, watching for tachycardia, agitation, fever, or vomiting

Large ingestion or symptomatic patient Referral; activated charcoal if early and airway is protected; beta-blocker (propranolol) for adrenergic symptoms

Liothyronine (T3) ingestion Higher concern: effects begin within 6 to 12 hours because no conversion is required

Severe toxicity (rare) Thyroid-storm-like state with hyperthermia, dysrhythmias, and agitation: cooling, beta-blockade, benzodiazepines, and endocrine consultation

Counseling point: because the latency is days, follow-up calls for a thyroid hormone ingestion extend well beyond the usual 24-hour window.

Corticosteroids and Sex Hormones

The topic list also names steroids among the hormones. Acute ingestions are among the most reassuring calls a specialist handles.

Corticosteroids (prednisone, dexamethasone, hydrocortisone): a single acute overdose causes little beyond transient hyperglycemia, gastrointestinal upset, or insomnia. Toxicity comes from chronic use (adrenal suppression, Cushingoid effects) and from abrupt withdrawal after long-term therapy, which can precipitate adrenal crisis.

Oral contraceptives and estrogens : exploratory ingestions by children cause at most nausea, vomiting, and occasionally minor withdrawal vaginal bleeding in young girls days later; home observation is standard.

Anabolic steroids and testosterone : acute ingestion has low toxicity; chronic misuse causes erythrocytosis, hepatotoxicity, and cardiovascular effects.

Poison Center Case: One Tablet, Twenty-Four Hours

A grandmother calls because her 2-year-old grandson (12 kg) was found with her open pill organizer. One glyburide 5 mg tablet is missing. He is playing normally and his bedside glucose at the emergency department is 96 mg/dL four hours later. The physician asks whether the child can go home, since he is asymptomatic and euglycemic.

Specialist guidance. The CSPI explains that a normal glucose at 4 hours is expected and reassures no one: sulfonylurea hypoglycemia commonly begins 8 to 18 hours after ingestion. The recommendation is admission for at least 24 hours with hourly then two-hourly glucose checks, oral feeding, no prophylactic dextrose , and octreotide 1 to 1.25 mcg/kg available at the bedside to give with dextrose at the first documented hypoglycemic episode. Discharge is appropriate only after the child has gone at least 24 hours without hypoglycemia, counting from the last octreotide dose if any was given.